Vericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18,...
February 16 2021 - 8:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that Nick Colangelo, President and CEO, and Joe Mara,
CFO, will participate in a fireside chat at the BTIG Virtual
MedTech, Digital Health, Life Science & Diagnostic Tools
Conference on Thursday, February 18, 2021, at 3:00p.m. Eastern
Time.
A live webcast of the event will be available on the Investor
Relations section of the Vericel Corporation website at:
http://investors.vcel.com.
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company’s website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2021 Vericel
Corporation. All rights reserved.
Investor Contacts:Chad RubinSolebury
Troutcrubin@troutgroup.com+1 646-378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024